TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
MORRISTOWN, N.J., May 08, 2017 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2017, after the market close on Monday, May 15, 2017. John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
| Date: | Monday, May 15 | ||
| Time: | 4:30 PM ET | ||
| Toll free (U.S.): | 888-504-7953 | ||
| International: | 719-457-2643 | ||
| Conference ID: | 4336660 | ||
| Webcast: | http://public.viavid.com/index.php?id=124373 |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT Investor Relations Matthew P. Duffy, 212-915-0685 LifeSci Advisors, LLC [email protected]
